Animal studies of prophylaxis
- PMID: 9845495
- DOI: 10.1016/s0002-9343(97)00059-4
Animal studies of prophylaxis
Abstract
Antiviral and immune-based intervention strategies have been evaluated in vivo in animal models based on infections with lentiviruses and other retroviruses to explore their effect on preventing or limiting de novo virus infection. Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum. Prevention of the establishment of infection by PEP has been documented under defined experimental conditions. However, in the event that early intervention is not effective in preventing infection, evidence supporting control of viral replication and disease progression mediated by early intervention has also been reported. Thus, PEP may have a significant impact in preventing or altering viral replication in vivo and disease course.
Similar articles
-
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1167-73. doi: 10.1089/088922201316912772. AIDS Res Hum Retroviruses. 2001. PMID: 11522186
-
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.J Infect Dis. 2003 Aug 1;188(3):424-7. doi: 10.1086/376531. Epub 2003 Jul 10. J Infect Dis. 2003. PMID: 12870124
-
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).Antivir Chem Chemother. 2003 Jan;14(1):49-59. doi: 10.1177/095632020301400105. Antivir Chem Chemother. 2003. PMID: 12790516
-
Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.Intervirology. 1997;40(5-6):295-303. doi: 10.1159/000150563. Intervirology. 1997. PMID: 9675635 Review.
-
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003. Clin Pharmacokinet. 2004. PMID: 15217303 Review.
Cited by
-
Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).Infect Dis Clin North Am. 2014 Dec;28(4):601-13. doi: 10.1016/j.idc.2014.08.005. Epub 2014 Oct 5. Infect Dis Clin North Am. 2014. PMID: 25287589 Free PMC article. Review.
-
Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis.Am J Prev Med. 2013 Jan;44(1 Suppl 2):S80-5. doi: 10.1016/j.amepre.2012.09.036. Am J Prev Med. 2013. PMID: 23253767 Free PMC article. Review. No abstract available.
-
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting.Eur J Epidemiol. 2004;19(6):577-84. doi: 10.1023/b:ejep.0000032349.57057.8a. Eur J Epidemiol. 2004. PMID: 15330131 Review.
-
HIV Non-Occupational Post Exposure Prophylaxis in Nigeria: A Systematic Review of Research Evidence and Practice.Int J MCH AIDS. 2019;8(2):101-119. doi: 10.21106/ijma.287. Epub 2019 Nov 18. Int J MCH AIDS. 2019. PMID: 31803532 Free PMC article.
-
Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.Cancer Stud Ther. 2020 Jul;5(2):https://researchopenworld.com/towards-covid-19-prophylaxis-an-aids-preclinical-research-perspective/. Epub 2020 Jul 19. Cancer Stud Ther. 2020. PMID: 32905553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous